Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Sex steroids are major promoters of the growth of breast and prostate cancers. This Review
by Poutanen et al. describes the development of treatments for these cancer types that act to …

Castration resistant prostate cancer (CRPC) remains androgen dependant despite castrate
levels of circulating testosterone following androgen deprivation therapy, the first line of …

Background AR‐V7‐positive metastatic prostate cancer is a lethal phenotype with few
treatment options and poor survival. Methods The two‐cohort nonrandomized Phase 2 study …

Background Prostate cancer (PCa) is a major type of cancer in man worldwide. Androgen
deprivation therapy (ADT) and the next‐generation androgen receptor (AR) pathway …

Simple Summary Androgen receptor splice variants (AR-Vs) play an important role in
prostate cancer progression, especially as a putative resistance mechanism against AR …

Prostate cancer has become the second leading cancer in men worldwide. Androgen plays
an important role in normal functioning, development, and differentiation of the prostate, and …

Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …

Simple Summary Prostate cancer is the most common non-cutaneous malignancy among
men in the United States. Bone metastases and health are crucial issues in prostate cancer …

Background Genomic alterations to the androgen receptor (AR) are common in metastatic
castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand …